

Terminology Terminologie

Bulletin of the World Health Organization, 58 (6): 945-948

Nomenclature for factors of the HLA system, 1980*

This article outlines the decisions made by the WHO nomenclature committee on leukocyte antigens at a meeting held after the 8th International Workshop on Histocompatibility Testing. Particular attention is given to new designations for provisional HLA-B and HLA-DR specificities and the upgrading of certain HLA-D and HLA-DR specificities to full HLA status. The existence of supertypic cross-reacting specificities was confirmed and extended.

The HLA nomenclature committee met under the auspices of the World Health Organization and the International Union of Immunological Societies, after the 8th International Histocompatibility Testing Workshop, in order to consider revisions and additions to the nomenclature following the principles established in previous reports (1-5).

HLA-A, HLA-B, and HLA-C specificities

There are no changes or additions to the nomenclature for the HLA-A specificities.

There are no changes to the nomenclature for the previously identified HLA-B specificities. New designations for provisional HLA-B specificities are listed in Table 1. All are subdivisions or "splits" of previously identified specificities. At present, Bw59 (defined by extra reactions of some B8 antisera) is found predominantly in Oriental populations. The following suggested specificities were considered, but the committee felt that they were not sufficiently well defined to be given a provisional designation: 8w57^a (Bf, SN-2, Te90), 8w58 (5y, Te73), 8w59 (Bu, SV, K5, DA(6), 8w62 (14.2), 8w63 (14.1), 8w66 (Te74, 15.3).

As there has been no change in the nomenclature for the complement components coded for by genes in the HLA region, it has been decided to retain the Cw nomenclature for all the HLA-C locus specificities

* The report of the HLA nomenclature committee was first published in *Tissue antigens*, 16: 113-117 (1980). This terminology note, which was drafted by the signatories listed on page 946, is based on the report and is published by permission of Munksgaard International Publishers Ltd, Copenhagen. A French translation will be published in a future issue of the *Bulletin*.

^a 8w57, etc., were designations used during the 8th Workshop (6).

Table 1. New designations for provisional specificities of the HLA-B locus

New	Previous equivalents	8th Workshop nomenclature
HLA-Bw55	22.1	8w55
HLA-Bw56	22.2, Te92, Da30	8w56
HLA-Bw57	17.1, 17A, 17 long	8w67
HLA-Bw58	17.2, 17B, 17 short	8w68
HLA-Bw59	HOK-1, 8.2	8w69
HLA-Bw60	40.1	8w60
HLA-Bw61	40.2	8w61
HLA-Bw62	15.1, To53, 15B, Te72	8w64
HLA-Bw63	15.2, To52, 15A, Te71	8w65

(4), even though Cw1, Cw2, Cw3, Cw4, and Cw5 are sufficiently well defined to justify upgrading to full HLA nomenclature status. Cw6 remains difficult to define, especially in the presence of Cw4. Two new HLA-Cw specificities are given in Table 2.

Table 2. New designations for provisional specificities of the HLA-C locus

New	Previous equivalents	8th Workshop nomenclature
HLA-Cw7	Cve, CTo-1	BwCw7
HLA-Cw8	T8, T9	BwCw8, BwCw9

HLA-D specificities

The definition of the specificities Dw1, Dw2, Dw3, and Dw5 has improved but is still not good enough to allow the provisional w designation to be dropped. The inclusion of Dw11 in Dw7 was confirmed during the 8th Workshop, although Dw7 itself is difficult to define. The identification of Dw10 was much improved, whereas Dw4, Dw6, Dw8, and Dw9 are still poorly defined, with clear indications of heterogeneity for Dw4 and Dw6. One new specificity was defined in Oriental populations, namely HLA-Dw12, formerly DH0 or DB4 (8th Workshop designations) (6).

Other specificities discussed, but considered not sufficiently well defined to be given a provisional designation, include DB1 (associated with Dw7), DB2 (associated with Dw5), DB3, and DB5 (8th Workshop designations) (6).

HLA-DR specificities

The DR specificities upgraded to full HLA status are listed in Table 3. DRw6 retains its provisional status since the lack of operationally monospecific antisera makes its definition difficult. Three new provisional specificities are listed in Table 4. While the correlation between the previously well-established D and DR specificities remains unambiguous, it has become clear that the definition of new specificities has made it difficult to maintain the parallelism between the D and DR nomenclature. Thus DRw9 and DRw10 are not specifically associated with Dw9 and Dw10. Other specificities discussed, but not considered sufficiently well defined to be given a provisional designation, included 8w13, YYY or 5/6, and various suggested subdivisions of DRw6.

The existence of supertypic cross-reacting specificities, which had been partially identified during the 7th workshop (5), was confirmed during the 8th Workshop. The combinations (DR1, DR2, DRw6, DRw10), (DR3, DR5, DRw6, DRw8), and (DR4,

Table 4. New designations for provisional specificities of the HLA-DR locus

New	Previous equivalents	8th Workshop nomenclature
HLA-DRw8	WIA8	8wDRw8
HLA-DRw9	WIA4x7, DuB15	8wDRw12 included DRw9 and DRw10
HLA-DRw10	ST-1, LTM	8wDRw14

DR7, DRw9) were noted and given the designations MT1 (DC1), MT2, and MT3, respectively (6). It is not yet clear whether these supertypic antigens and certain other specificities discussed in the report of the 8th Workshop (6) are on the currently recognized DR locus molecular products, or on other locus products, or both. These, and other problems of definition of combinations of specificities need to be clarified by further analysis of the serological and genetic data and by other approaches, such as the use of monoclonal antibodies and detailed biochemical analysis.

* * *

Table 3. New designations for HLA-DR specificities that have been upgraded to full HLA status

New	Previous
HLA-DR1	HLA-DRw1
HLA-DR2	HLA-DRw2
HLA-DR3	HLA-DRw3
HLA-DR4	HLA-DRw4
HLA-DR5	HLA-DRw5
HLA-DR7	HLA-DRw7

- E. Albert, Kinderpoliklinik der Universität, Munich, Germany
 D. B. Amos, Duke Medical Center, Durham, NC, USA (*Chairman*)
 W. F. Bodmer, Imperial Cancer Research Fund Laboratories, London, England (*Rapporteur*)
 R. Ceppellini, Institute for Immunology, Basel, Switzerland
 J. Dausset, Institut de Recherches sur les Maladies du Sang, Hôpital Saint-Louis, Paris, France
 F. Kissmeyer-Nielsen, The University Hospital, Aarhus, Denmark
 W. Mayr, Institut für Blutgruppenserologie, Vienna University, Vienna, Austria
 R. Payne, Stanford University School of Medicine, Stanford, California, USA (*Rapporteur*)
 J. J. van Rood, University of Leiden, Leiden, The Netherlands
 P. I. Terasaki, UCLA School of Medicine, University of California, Los Angeles, California, USA
 R. L. Walford, UCLA School of Medicine, University of California, Los Angeles, California, USA

Nomenclature for factors of the HLA system, 1980

Page 946, right-hand column

delete: lines 3 – 5, and replace by:

“... yet clear whether these supertypic and certain other specifications are on the currently recognized DR...”

Vol. 59, No. 2

International collaborative study on juvenile hypertension 1. Study procedures and screening data

Page 295, authors' names

delete: E. TÖRÖK,¹ I. GYÁRFÁS,² & M. CSUKÁS³

insert: INTERNATIONAL COLLABORATIVE GROUP¹

Page 295. Replace the footnotes *, 1, 2, and 3 by a new footnote as follows:

¹ The names of the research centres and investigators involved in this study are listed in Annex 1 on page 304. This article was prepared on behalf of the International Collaborative Group by E. Török, I. Gyárfás, and M. Csukás. Requests for reprints should be addressed to Dr E. Török, Department of Cardiology, Hungarian Institute of Cardiology, H-1450 Budapest, P.O.B. 88, Hungary.

Table 5. Complete listing of recognized HLA specificities^a

HLA-A	HLA-B	HLA-C	HLA-D	HLA-DR
HLA-A1	HLA-B5	HLA-Cw1	HLA-Dw1	HLA-DR1
HLA-A2	HLA-B7	HLA-Cw2	HLA-Dw2	HLA-DR2
HLA-A3	HLA-B8	HLA-Cw3	HLA-Dw3	HLA-DR3
HLA-A9	HLA-B12	HLA-Cw4	HLA-Dw4	HLA-DR4
HLA-A10	HLA-B13	HLA-Cw5	HLA-Dw5	HLA-DR5
HLA-A11	HLA-B14	HLA-Cw6	HLA-Dw6	HLA-DRw6
HLA-Aw19	HLA-B15	HLA-Cw7	HLA-Dw7	HLA-DR7
HLA-Aw23(9)	HLA-Bw16	HLA-Cw8	HLA-Dw8	HLA-DRw8
HLA-Aw24(9)	HLA-B17		HLA-Dw9	HLA-DRw9
HLA-A25(10)	HLA-B18		HLA-Dw10	HLA-DRw10
HLA-A26(10)	HLA-Bw21		HLA-Dw11	
HLA-A28	HLA-Bw22		HLA-Dw12	
HLA-A29	HLA-B27			
HLA-Aw30	HLA-Bw35			
HLA-Aw31	HLA-B37			
HLA-Aw32	HLA-Bw38(w16)			
HLA-Aw33	HLA-Bw39(w16)			
HLA-Aw34	HLA-B40			
HLA-Aw36	HLA-Bw41			
HLA-Aw43	HLA-Bw42			
	HLA-Bw44(12)			
	HLA-Bw45(12)			
	HLA-Bw46			
	HLA-Bw47			
	HLA-Bw48			
	HLA-Bw49(w21)			
	HLA-Bw50(w21)			
	HLA-Bw51(5)			
	HLA-Bw52(5)			
	HLA-Bw53			
	HLA-Bw54(w22)			
	HLA-Bw55(w22)			
	HLA-Bw56(w22)			
	HLA-Bw57(17)			
	HLA-Bw58(17)			
	HLA-Bw59			
	HLA-Bw60(40)			
	HLA-Bw61(40)			
	HLA-Bw62(15)			
	HLA-Bw63(15)			
	HLA-Bw4 ^b			
	HLA-Bw6			

^a The listing of broad specificities in parentheses after a narrow specificity, e.g., HLA-Aw23(9) is optional. The following arose as clear-cut splits of other specificities.

HLA-A9	into	Aw23, Aw24
HLA-A10	into	A25, A26
HLA-B5	into	Bw51, Bw52
HLA-B12	into	Bw44, Bw45
HLA-B15	into	Bw62, Bw63
HLA-Bw16	into	Bw38, Bw39
HLA-B17	into	Bw57, Bw58
HLA-Bw21	into	Bw49, Bw50
HLA-Bw22	into	Bw54, Bw55, Bw56
HLA-B40	into	Bw60, Bw61

^b The following are the generally agreed inclusions of HLA-B specificities in Bw4 and Bw6:

Bw4:	B13, B27, B37, Bw38(w16), Bw44(12), Bw47, Bw49(w21), Bw51(5), Bw52(5), Bw53, Bw57(17), Bw58(17), Bw59, Bw63(15)
Bw6:	B7, B8, B14, B18, Bw35, Bw39(16), Bw41, Bw42, Bw45(12), Bw46, Bw48, Bw50(w21), Bw54(w22), Bw55(w22), Bw56(w22), Bw60(40), Bw61(40), Bw62(15)

ACKNOWLEDGEMENTS

The contributions of Dr Domenico Bernoco, Dr Min Sik Park, Dr M. R. Mickey, Dr Bo Dupont, and Dr Edmund Yunis, who acted as co-opted members of the committee for the meeting that led to the preparation of this report, are gratefully acknowledged.

REFERENCES

1. *Bulletin of the World Health Organization*, **39**: 483 (1968).
 2. *Bulletin of the World Health Organization*, **47**: 659 (1972).
 3. *Bulletin of the World Health Organization*, **52**: 261 (1975).
 4. *Bulletin of the World Health Organization*, **56**: 461 (1978).
 5. BODMER, W. ET AL., ed., *Histocompatibility testing 1977*. Copenhagen, Munksgaard, 1978.
 6. TERASAKI, P. I., ed., *Histocompatibility testing 1980*. Los Angeles, California, UCLA Tissue Typing Laboratory, 1980.
-